Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial

Author(s): PierFranco Conte, MD, PhD1,2; Giancarlo Bisagni, MD3; Federico Piacentini, MD, PhD4; Samanta Sarti, MD, PhD5; Santino Minichillo, MD6; Elisa Anselmi, MD7; Michele Aieta, MD8; Vittorio Gebbia, MD9; Alessio Schirone, MD10; Antonino Musolino, MD, PhD11; Ornella Garrone, MD, PhD12; Alessandra Beano, MD13; Anita Rimanti, MD14; Francesco Giotta, MD15; Anna Turletti, MD16; Federica Miglietta, MD17,18; Maria Vittoria Dieci, MD17,18; Roberto Vicini, PhD19; Sara Balduzzi, MD20; Robert D’Amico, PhD4; and Valentina Guarneri, MD, PhD17,18
Source: DOI: 10.1200/JCO.23.00790 Journal of Clinical Oncology 41, no. 32 (November 10, 2023) 4976-4981.
Original Article
Professional photo of Anjan J Patel, MD

Dr. Anjan Patel's Thoughts

This is a 10-year follow-up of the ShortHER study using nine weeks vs. 12 months of adjuvant trastuzumab in HR+ non-metastatic breast cancer.  With long-term follow-up, non-inferiority could not be claimed statistically. Still, the DFS/OS results are identical in those patients with N0-N3 disease, while those with N4 disease seemed to have a significant difference favoring 12 months of therapy, suggesting that volume/burden of disease drives the margin of benefit in adjuvant trastuzumab therapy.
We present the final analysis of the phase III noninferiority, randomized ShortHER trial comparing 9 weeks versus 1 year of adjuvant trastuzumab with chemotherapy in patients with human epidermal growth factor receptor 2–positive (HER2+) early breast cancer (BC). Women with HER2+ BC were randomly assigned to anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or 9-week trastuzumab (arm B, short). Here, we report the second coprimary end point overall survival (OS), updated disease-free survival (DFS), and outcomes according to hormone receptor status, age, and nodal status. At a median follow-up of 9 years, 10-year DFS is 77% versus 78% in the long versus short arm, respectively. Ten-year OS is 89% versus 88% in the long versus short arm, respectively. 10-year DFS rates in the long versus short arm according to nodal status are N0 81% versus 85%; N1-3 77% versus 79%; and N4+ 63% versus 53%. Ten-year OS rates in long versus short arm according to nodal status are N0 89% versus 95%%; N1-3 92% versus 89%; and N4+ 84% versus 64%. The updated analysis of the ShortHER trial shows that 1-year trastuzumab is the standard treatment for patients with HER2+ early BC as noninferiority cannot be claimed. However, numerically, the differences for the patients at low or intermediate risk (N0/N1-3) is negligible, while patients with N4+ have a clear benefit with 1-year trastuzumab.

Author Affiliations

1S Camillo Hospital, IRCCS, Venezia, Italy; 2University of Padova, Padova, Italy; 3Department of Oncology and Advanced Technologies, Azienda USL-IRCCS, Reggio Emilia, Italy; 4Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy; 5IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori,” IRST srl, Meldola, Italy; 6Medical Oncology, Bellaria Hospital, Bologna, Italy; 7Department of Oncology and Hematology, ASL Piacenza, Piacenza, Italy; 8Medical Oncology, IRCCS-CROB, Rionero in Vulture, Italy; 9Kore University, Enna and La Maddalena Clinic, Palermo, Italy; 10S Anna University Hospital, Ferrara, Italy; 11University Hospital, Parma, Italy; 12IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 13Breast Oncology, Città della Salute e della Scienza, Torino, Italy; 14Carlo Poma Hospital, ASST Mantova, Mantova, Italy; 15IRCCS Istituto Oncologico Giovanni Paolo II, Bari, Italy; 16Senology, Ospedale Martini, ASL Città di Torino, Torino, Italy; 17Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; 18Oncology 2, Veneto Oncology Institute, IOV-IRCCS, Padova, Italy; 19Statistical Unit, University Hospital, Modena, Italy; 20University of Modena and Reggio Emilia, Modena, Italy

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

ASCENT-03 shows that in first-line, PD-1/PD-L1–ineligible advanced TNBC, sacituzumab improves PFS to 9.7 vs 6.9 months and extends median duration of response (DOR) to 12.2 vs 7.2 months, with similar overall response rate (ORR) (48% vs 46%) and immature overall survival (OS) (21.5 vs 20.2 months) Grade ≥3. Adverse events (AEs) were comparable (66% vs 62%), but sacituzumab had more neutropenia and diarrhea, fewer discontinuations (4% vs 12%), and early-cycle infection-related deaths in patients without primary G-CSF. For PD-1/PD-L1–ineligible mTNBC, SG offers more durable control than chemo with manageable myelosuppression — so consider SG first-line and start G-CSF early in higher-risk patients.

Read More »

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly utilizes the ubiquitin–proteasome system. It was compared to fulvestrant in patients who had received one prior line of hormonal therapy with a CDK4/6 inhibitor. Among patients with ESR1 mutations, Vepdegestrant demonstrated a median progression-free survival (PFS) of 5.0 months versus 2.1 months with fulvestrant. In the overall population, the median PFS was 3.8 months for Vepdegestrant and 3.6 months for fulvestrant, indicating that the drug showed particular efficacy in tumors harboring ESR1 mutations.

Read More »

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

Elinzanitant, a neurokinin-targeted therapy, has been shown to reduce vasomotor symptoms compared to placebo. These symptoms are one of the reasons some of my patients discontinue aromatase inhibitor (AI) therapy, so Elinzanitant presents a promising alternative to help manage these side effects. Additionally, Fezolinetant is already approved and available on the market.

Read More »
Load More